A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)-HIV and gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution of alum with the more immunogenic MF59 adjuvant is under consideration for the next efficacy human trial. We found here that an ALVAC-simian immunodeficiency virus (SIV) and gp120 alum (ALVAC-SIV + gp120) equivalent vaccine, but not an ALVAC-SIV + gp120 MF59 vaccine, was efficacious in delaying the onset of SIVmac251 in rhesus macaques, despite the higher immunogenicity of the latter adjuvant. Vaccine efficacy was associated with alum-induced, but not with MF59-induced, envelope (Env)-dependent mucosal innate lymphoid cells (ILCs) that produce interleukin (IL)-17, as well as with mucosal IgG to the gp120 variable region 2 (V2) and the expression of 12 genes, ten of which are part of the RAS pathway. The association between RAS activation and vaccine efficacy was also observed in an independent efficacious SIV-vaccine approach. Whether RAS activation, mucosal ILCs and antibodies to V2 are also important hallmarks of HIV-vaccine efficacy in humans will require further studies.
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition / M. Vaccari, S.N. Gordon, S. Fourati, L. Schifanella, N.P.M. Liyanage, M. Cameron, B.F. Keele, X. Shen, G.D. Tomaras, E. Billings, M. Rao, A.W. Chung, K.G. Dowell, C. Bailey Kellogg, E.P. Brown, M.E. Ackerman, D.A. Vargas Inchaustegui, S. Whitney, M.N. Doster, N. Binello, P. Pegu, D.C. Montefiori, K. Foulds, D.S. Quinn, M. Donaldson, F. Liang, K. Loré, M. Roederer, R.A. Koup, A. Mcdermott, Z. Ma, C.J. Miller, T.B. Phan, D.N. Forthal, M. Blackburn, F. Caccuri, M. Bissa, G. Ferrari, V. Kalyanaraman, M.G. Ferrari, D. Thompson, M. Robert Guroff, S. Ratto Kim, J.H. Kim, N.L. Michael, S. Phogat, S.W. Barnett, J. Tartaglia, D. Venzon, D.M. Stablein, G. Alter, R. Sekaly, G. Franchini. - In: NATURE MEDICINE. - ISSN 1078-8956. - 22:7(2016), pp. 762-770. [10.1038/nm.4105]
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition
M. VaccariPrimo
;L. Schifanella;F. Caccuri;M. Bissa;M.G. Ferrari;
2016
Abstract
A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)-HIV and gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution of alum with the more immunogenic MF59 adjuvant is under consideration for the next efficacy human trial. We found here that an ALVAC-simian immunodeficiency virus (SIV) and gp120 alum (ALVAC-SIV + gp120) equivalent vaccine, but not an ALVAC-SIV + gp120 MF59 vaccine, was efficacious in delaying the onset of SIVmac251 in rhesus macaques, despite the higher immunogenicity of the latter adjuvant. Vaccine efficacy was associated with alum-induced, but not with MF59-induced, envelope (Env)-dependent mucosal innate lymphoid cells (ILCs) that produce interleukin (IL)-17, as well as with mucosal IgG to the gp120 variable region 2 (V2) and the expression of 12 genes, ten of which are part of the RAS pathway. The association between RAS activation and vaccine efficacy was also observed in an independent efficacious SIV-vaccine approach. Whether RAS activation, mucosal ILCs and antibodies to V2 are also important hallmarks of HIV-vaccine efficacy in humans will require further studies.
| File | Dimensione | Formato | |
|---|---|---|---|
|
nm.4105.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
2.97 MB
Formato
Adobe PDF
|
2.97 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
